EchoSolv AS vs iCAC Device
AI Verdict
Choose EchoSolv AS if…
Choose EchoSolv AS if your primary goal is to enhance the accuracy and efficiency of severe aortic stenosis detection from echocardiograms. This tool is ideal for cardiology departments seeking AI-powered clinical decision support to consistently identify high-probability sAS patients and prioritize studies for closer review, seamlessly integrating into existing PACS workflows without requiring EMR integration.
View EchoSolv AS →Choose iCAC Device if…
Choose iCAC Device if you aim to opportunistically detect and quantify coronary artery calcium from routine, non-contrast chest CT scans to aid in early cardiovascular disease detection. This solution is best suited for radiology and cardiology practices looking to leverage existing imaging data to provide adjunctive information to radiologists and offer a quantitative assessment of CAC burden for broader patient risk stratification.
View iCAC Device →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | EchoSolv AS | iCAC Device |
|---|---|---|
| Pricing | Unknown | Contact for pricing |
| Deployment | Cloud-based | Software as a Medical Device (SaMD), integrates with PACS or DICOM router. Cloud-based (via Carebricks platform). |
| BAA Available | Yes AI-estimated | Unknown |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Unknown |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
EchoSolv ASEchoSolv AS is designed for minimal workflow disruption, explicitly stating 'no EMR integration required' and 'integrates with PACS,' alongside ultra-fast risk detection in under 3 seconds. This suggests a simpler and quicker integration and usage process for clinicians compared to Tool B, which, while integrating with PACS and EHRs, does not highlight the same speed or ease of initial setup.
Clinical Value
EchoSolv ASBoth tools are FDA-cleared and offer significant clinical value. However, EchoSolv AS provides direct decision support for a severe, time-sensitive condition (severe aortic stenosis) with reported near-perfect accuracy and offers 'second reader support' to help prioritize studies for closer review. While iCAC Device offers valuable opportunistic early detection of cardiovascular risk, EchoSolv AS's focus on a critical, urgent diagnosis with high accuracy gives it a slight edge in immediate clinical actionability.
Pricing & Value
EchoSolv ASEchoSolv AS provides some transparency regarding its subscription-based revenue model and has identified a miscellaneous reimbursement code (93799) with an expected rate of US$100-US$150 per use, while actively pursuing a dedicated Category III CPT code. In contrast, iCAC Device only states 'contact for pricing' and lacks any public information on reimbursement pathways, making its financial value proposition less clear.
Enterprise Readiness
EchoSolv ASEchoSolv AS explicitly states it is HIPAA compliant and has a Business Associate Agreement (BAA) in place, which are critical contractual and compliance requirements for enterprise adoption in the US healthcare system. While iCAC Device is FDA-cleared and cloud-based, it requires contacting the vendor for BAA and HIPAA details, indicating less upfront transparency regarding these essential enterprise readiness factors.
Innovation
iCAC DeviceThe iCAC Device's ability to opportunistically detect and quantify coronary artery calcium from routine, non-contrast, non-gated chest CT scans is highly innovative. This leverages existing imaging data to screen for a widespread cardiovascular risk factor without requiring additional dedicated scans, offering significant potential for population health screening and early intervention. While EchoSolv AS's measurement-based AI is also innovative, Tool B's application has a broader, more impactful screening potential.
Support & Docs
EchoSolv ASEchoSolv AS's company, Echo IQ, explicitly mentions a dedicated support team and an 'extensive suite of supporting documentation' to assist users and streamline processes like reimbursement. While Bunkerhill Health has a company website, specific public details about support services or documentation for the iCAC Device were not readily available through web searches, making Tool A appear more robust in this dimension.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | EchoSolv AS | iCAC Device |
|---|---|---|
| Name | EchoSolv AS | iCAC Device |
| Company | Echo IQ | Bunkerhill Health |
| Description | EchoSolv AS is an FDA-cleared, AI-powered clinical decision support platform by Echo IQ that analyzes echocardiograms to identify patients at risk for severe aortic stenosis with high accuracy and efficiency, integrating into existing workflows. | Bunkerhill Health's iCAC Device is an FDA-cleared AI algorithm that detects and quantifies coronary artery calcium from routine, non-contrast, non-gated chest CT scans, aiding in early cardiovascular disease detection. |
| Categories | Cardiology AI, Clinical Decision Support & Reference | Cardiology AI |
| Specialties | Cardiology, Cardiothoracic Surgery | Cardiology, Radiology |
| Key Features | AI-powered clinical decision support for severe aortic stenosis probability; Consistent severe AS probability and guideline check from measurements; Second reader support to help prioritize studies for closer review; Real-world readiness; AI does not use LVOT measurements; Faster clinical review using standardized, measurement-based AI and guideline analysis; Measurement-based AI (analyzes numerical measurements, not images); Designed to fit existing workflows (no EMR integration required, integrates with PACS); Ultra-fast risk detection (under 3 seconds) | Estimates presence and quantity of coronary artery calcium (CAC); Analyzes routine, non-contrast, non-gated chest CT scans; Utilizes deep-learning algorithms for analysis; Provides adjunctive information to radiologists; Outputs visual representation of estimated CAC segmentation; Delivers exact and four-category quantitative estimates of CAC burden in Agatston units; Integrates with EHRs via the Carebricks platform; Supports opportunistic identification of CAC from existing CT scans |
Videos
Demos, reviews, and walkthroughs featuring EchoSolv AS and iCAC Device.